Skip to content

Alligator Bioscience

  •  
    • Se
  • Startpage
  • About Alligator
    • Board of Directors
    • Senior Management
    • Career
  • Research and development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • ATOR-4066
      • ALG.APV-527
    • Scientific publications
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination Committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and owner information
    • Sharegraph
    • Analysts
    • Corporate deck
    • Capital raisings
      • Preferential Rights Issue Q1 2025
    • Financial reports
      • Interim reports
      • Year End Reports
      • Annual reports
    • Financial calendar
    • Presentations
  • Business Development
  • Press releases
  • Contact
  • Events

  1. Startpage
  2. News
Key downloads
Alligator Bioscience AB reports financial results for Q2 2025 and provides a business updateBulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2025Alligator Bioscience AB reports financial results for Q1 2025 and provides a business updateAlligator Bioscience publishes Annual Report for 2024Bulletin from the extraordinary general meeting in Alligator Bioscience AB
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
All IRRegulatoryReport
View as grid View as list
2024-12-022024-12-02
Regulatory

Alligator Bioscience carries out a rights issue of units of approximately SEK 280 million and raises bridge loans

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Continue reading
2024-11-19
Regulatory

Alligator announces sale of future financial commitments for two bispecific antibodies to Orion Corporation

Transaction valued at €3.5 million The partners have enjoyed a successful discovery collaboration since 2021 Lund, Sweden – Allig ...
Continue reading
2024-11-112024-11-11

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Alligator Bioscience and Aptevo Therapeutics report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, with ...
Continue reading
2024-11-06

Alligator Bioscience Presents an Update with Clinical and Biomarker Results with Mitazalimab in Phase 2 Pancreatic Cancer at SITC 2024

The data contain efficacy results and correlative outcomes with biomarkers based on a median follow-up of 18 months in OPTIMIZE-1 trial Conf ...
Continue reading
2024-10-31
Regulatory

Nomination Committee appointed in respect of AGM 2025 in Alligator Bioscience AB

Lund, Sweden, October 31, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in prepa ...
Continue reading
2024-10-30

Alligator Bioscience to Participate in Upcoming Scientific and Investor Conferences in Q4 2024

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces participation in the following conferences during Q4 202 ...
Continue reading
2024-10-29

Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024

LUND, SWEDEN and SEATTLE WA / October 29, 2024 / Alligator Bioscience AB (“Alligator”) (ATORX) and Aptevo Therapeutics (“A ...
Continue reading
2024-10-24
Regulatory

Alligator Bioscience AB reports financial results for the first 9 months of 2024 and for Q3 2024 and provides a business update

Recruitment completed of 450 µg/kg back-fill cohort in the mitazalimab OPTIMIZE-1 study in pancreatic cancer Positive interim Phase 1 ...
Continue reading
2024-09-16

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor Types Prolonged stable disease lasting >11 months demonstrate ...
Continue reading

Posts navigation

Older posts
Newer posts
  1. Startpage
  2. News
About Alligator

Alligator, a clinical-stage biotechnology company, develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Links
  • About Alligator
  • R&D
  • Corporate governance
  • Investors
  • News
  • Business Development
  • Privacy Policy
  • Glossary
Contact us

Headquarter
Alligator Bioscience AB
Medicon Village
Scheeletorget 1
SE-223 81 Lund Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Follow us

  

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

  • © Copyright 2024 – Alligator Bioscience AB

  • Privacy Policy | Use of Cookies |  Change your cookie settings here.

  • Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.
Settings Accept all
Cookies
Do your settings below. Or read our cookie policy.
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all